Antibiotics need a special place in the drug pricing debate - STAT

Antibiotics need a special place in the drug pricing debate - STAT

I think all 3 companies had enough evidence from actual experience selling to indicate it was not realistic to reach their intial goals. Tetraphase made completely wrong assumptions about how much Xerava they would sell pre-launch. But more than a year after launch, it is completely clear that even if they increase revenues by 10x, they will still be bleeding cash.



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More